Liquid biopsies have emerged as aversatile diagnostic solution, especially for cases when conventional(invasive) diagnostic tests are inconclusive or when the clinical condition isrelated to an organ that is not amenable to biopsy access
Roots Analysis is pleased to announce the publication of its recent study,titled, “Liquid Biopsy and Other Non-Invasive Cancer DiagnosticsMarket (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such asCTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”
Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of this approach over the next decade.It features an in-depth analysis, highlighting the capabilities of variousstakeholders engaged in this domain. In addition to other elements, the studyincludes:
§ A detailed review ofthe overall landscape of the non-invasive cancer diagnostics market.
§ An analysis of thevarious partnerships pertaining to non-invasive cancer diagnostics, which havebeen established between 2016 and 2019.
§ An analysis of theinvestments made in companies engaged in the development of non-invasive cancerdiagnostics.
§ An analysis of theinitiatives of big pharma players.
§ A detailedacquisition target analysis.
§ Elaborate profiles ofthe key players engaged in this domain.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
§ Type of Tumor Marker
§ ctDNA
§ cfDNA
§ CTCs
§ Exosomes
§ Others
§ Application
§ Diagnosis / Early Diagnosis
§ Patient Monitoring
§ Recurrence Monitoring
§ Target CancerIndication
§ Breast Cancer
§ Lung Cancer
§ Colorectal Cancer
§ Prostate Cancer
§ Bladder Cancer
§ Melanoma
§ Gastric Cancer
§ Pancreatic Cancer
§ Ovarian Cancer
§ Others
§ End Users
§ Hospitals
§ Research Institutes
§ Others
§ Key Geographical Regions
Press Release: Variation 1 (Format 2)
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
Key companies covered in the report:
§ Amoy Diagnostics
§ DiaCarta
§ HaploX Biotechnology
§ NeoGenomics
§ QIAGEN
§ Swift Biosciences
§ Sysmex Inostics
§ Thermo Fisher Scientific
Formore information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Other recent offerings
1. Companion DiagnosticsMarket (2nd Edition), 2019-2030
2. NovelTechnologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030
3. Cancer BiomarkersMarket:Focus on TMB, MSI / MMR and TILs Testing, 2019-2030
About Roots Analysis
Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots AnalysisPrivate Limited
Gaurav Chaudhary
+1 (415) 800 3415
